
Neuroendocrine/ Endocrine
Poorly Differentiated-NEC (any extrapulmonary neuroendocrine carcinoma with small cell or large cell histology)
10402: BAY1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)
Neuroendocrine Cancer
*10558: A phase II randomized control trial of triapine plus lutetium 177 dotatate versus lutetum 177 dotatate alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors
GI (Gastroenteropancreatic / Pancreatic tumors)
10388: A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
10450: A Phase 1b Study of M3814 (Peposertib) in Combination with Lutetium 177 Dotatate in Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
*10479: A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors
Prostate Cancer
*10487: A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation